We use cookies to help us improve the website and your experience using it.
You may delete and block all cookies from this site at any time. However,
please note this may result in parts of the site no longer working correctly.
If you continue without changing your settings we will assume you are happy to receive all cookies on this site.

First subject screened in global study

Congratulations to Dr Nicholas Webb and the Wellcome
Trust Children's Clinical Research Facility team who screened the
first patient globally to the Medicines for Children Research
Network study TAK491 in hypertensive children.

This was the first Greater Manchester study within the North
West Exemplar programme to recruit the all important first global
patient.

The study manager at Takeda commented: "As well as this being a
major achievement for the Wellcome Trust Children's Clinical
Research Facility and the Medicines for Children Research Network,
this is Takeda's first global paediatric trial of which the team
has achieved the first subject screened, with their imminent
enrolment"

"The team have proved that the UK is capable of leading subject
recruitment and achieving that first subject screened. Thank you
for the continued support and enthusiasm for this study."